In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Viking Therapeutics Inc’s stock clocked out at $27.98, down -4.44% from its previous closing price of $29.28. In other words, the price has decreased by -$4.44 from its previous closing price. On the day, 2.43 million shares were traded. VKTX stock price reached its highest trading level at $29.56 during the session, while it also had its lowest trading level at $27.76.
Ratios:
To gain a deeper understanding of VKTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 33.09 and its Current Ratio is at 33.09. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on February 13, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $102.
On February 07, 2025, Citigroup started tracking the stock assigning a Neutral rating and target price of $38.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 06 ’25 when Lian Brian sold 194,490 shares for $42.75 per share. The transaction valued at 8,313,601 led to the insider holds 2,366,570 shares of the business.
Mancini Marianna sold 54,215 shares of VKTX for $2,317,599 on Jan 06 ’25. The Chief Operating Officer now owns 374,134 shares after completing the transaction at $42.75 per share. On Jan 06 ’25, another insider, ZANTE GREG, who serves as the Chief Financial Officer of the company, sold 50,309 shares for $42.75 each. As a result, the insider received 2,150,595 and left with 165,259 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VKTX now has a Market Capitalization of 3286614784 and an Enterprise Value of 2239200768.
Stock Price History:
The Beta on a monthly basis for VKTX is 0.75, which has changed by -0.6642668 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, VKTX has reached a high of $89.10, while it has fallen to a 52-week low of $24.41. The 50-Day Moving Average of the stock is -9.50%, while the 200-Day Moving Average is calculated to be -44.22%.
Shares Statistics:
It appears that VKTX traded 4.35M shares on average per day over the past three months and 3783050 shares per day over the past ten days. A total of 111.57M shares are outstanding, with a floating share count of 108.95M. Insiders hold about 2.94% of the company’s shares, while institutions hold 73.46% stake in the company. Shares short for VKTX as of 1740700800 were 23912963 with a Short Ratio of 5.50, compared to 1738281600 on 23930853. Therefore, it implies a Short% of Shares Outstanding of 23912963 and a Short% of Float of 28.54.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are keenly observing as 11.0 analysts analyze and rate the current performance of Viking Therapeutics Inc (VKTX) in the stock market.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.19 and low estimates of -$0.43.
Analysts are recommending an EPS of between -$0.98 and -$2.16 for the fiscal current year, implying an average EPS of -$1.55. EPS for the following year is -$2.12, with 14.0 analysts recommending between -$1.4 and -$3.1.
